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Biological advances have radically expanded our insights into the underpinnings of health and
disease. New knowledge has formed the substrate for translation - expedited in turn by the
biotechnology and pharmaceutical industry into novel therapeutic solutions impacting the
management of patients and populations. Indeed, this Bioinnovation Enterprise has become
the dominant growth sector in drug development and the engine driving the translation of
breakthrough therapies worldwide. This annual Therapeutic Innovations issue highlights
recent exceptional advances by the Bioinnovation Enterprise in translating molecular insights
in pathobiology into transformative therapies.
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Changes call for innovation, and innovation leads to progress
Li Keqiang
The revolution in biological discovery and previously unanticipated strides in technology
are transforming patient management and healthcare delivery.1 This transformation reflects
the logarithmic growth in molecular innovation driven by public investment in creating
platforms for healthcare solutions that benefit populations, now and for future generations.2
This scientific evolution propels the development of precision solutions, exploiting insights in
pathophysiology at the molecular level that provides mechanism-based targets for advanced
therapies, amplifies the ability to affect cures, and eliminates adverse events.3 Indeed, the
growing toolbox of next-generation platforms has produced unprecedented opportunities to
personalize pharmacological and technological therapies that can be positioned across the
spectrum of diseases, populations, and geographies to reach the global community.4 In turn,
the emerging framework established by molecularly targeted diagnostic and therapeutic
paradigms transforms the traditional one-size-fits-all approach to patient management into
individualized healthcare solutions.5
The profound impact of this scientific revolution on global health can best be
appreciated by considering the overwhelming success of the output of therapeutic innovation
in the biotechnology and biopharmaceutical sector recently highlighted in this journal.6 Indeed,
in the last 30 years, this “Bioinnovation Enterprise” has emerged as one of the largest growth
sectors in drug development, with >200 therapies emerging for >250 indications from >4,000
biotechnology companies worldwide with a combined value of $185 billion. In 2012,
biotechnology product sales worldwide were an estimated $163 billion, which constituted
~19% of the total prescription product sales. Of 119 overall products categorized as
blockbusters (sales over $1 billion per year), 47 (39%) were biotechnology products. The
prominence of this sector in therapeutic innovation is reflected by the fact that the
overwhelming majority of new molecular entities approved by the FDA over the last 3 years,
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and those predicted to transform the care of patients in their respective disease classes, are
products of the evolving Bioinnovation Enterprise.7, 8
Case in point, the impact of this innovation is highlighted by emerging paradigms for the
management of asthma.9 This disease currently afflicts 300 million people globally, a number
which is expected to rise to 400 million by 2020. While most patients are satisfactorily
controlled on established treatments, 5% remain poorly controlled. In that context, innovative
treatments have the potential to provide options for these unfortunate patients. Moreover, the
economic and healthcare benefits of treating poorly controlled asthma are substantial and in
Europe the total cost of asthma is ~€17.7 billion. Mitchell, El-Gammal, and O’Byrne9 highlight
how this field has been transformed by mechanistic insights gained in molecular mechanisms
underlying epithelial inflammation. Allergens bind to surface receptors on bronchial epithelial
cells releasing a number of cytokines which initiate inflammatory cascades. They mobilize and
activate inflammatory T cells, eosinophils, and basophils which secrete other cytokines,
promoting IgE synthesis from B-cells and increasing airway hyper-responsiveness, mucus
hypersecretion and airway remodeling that are canonical features of allergic asthma. The
identification of these cytokines, their receptors, and their roles in the inflammatory cascade
have yielded targets for humanized monoclonal antibodies that interrupt select pathways
essential to the pathobiology of allergic asthma. There are more than 20 therapeutic
monoclonal antibodies either approved or in various stages of clinical development that target
molecular components of the inflammatory cascade. Progression of these agents through their
developmental programs will transform the management of refractory allergic asthma globally.
Beyond airways, insights in cytokine cascades mediating inflammation has provided
remarkable opportunities in the management of inflammatory bowel disease (IBD), including
Crohn’s disease (transmural inflammation) and ulcerative colitis (mucosal inflammation).10 This
continuum of diseases afflicts about 10,000 new patients each year, with a prevalence of about
500,000 patients in the U.S. The most impactful advance in the management of IBD over the past
20 years has been the development of monoclonal antibodies directed to tumor necrosis factor
4

alpha (TNF-α). Unfortunately, although anti-TNF agents are effective, only ~50% of patients achieve
clinical remission, long term corticosteroid-free remission rates are only 20-30%, and there is a
significant loss of response reflecting the formation of neutralizing antibodies. Moreover, while
anti-TNF agents reduce inflammation, they do not block the underlying pathogenic triggers and
treatment cessation is associated with disease within one year in more than 50% of patients. These
considerations highlight the unmet clinical need for novel agents to manage IBD. While approaches
in clinical development include monoclonal antibodies to inflammatory cytokines, Vanhoe, Nys, and
Vermiere10 review other novel approaches that leverage recent mechanistic insights into molecular
mechanisms underlying mucosal inflammation. Indeed, IBD is characterized by the influx of

immune cells into inflamed sites in the mucosa mediated by adhesion molecules suggesting the
potential therapeutic value of strategies targeting anti-leukocyte migration. Vedolizumab, a
monoclonal antibody targeting α4β7 ligand which is responsible for the trafficking of
lymphocytes to the inflamed gut, was recently approved by US and European regulatory
agencies and is a major advance for the management of patients with IBD. 8,
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Similarly,

transforming growth factor (TGF)-β is a cytokine mediating counter-regulatory mechanisms
modulating inflammation. In turn, the anti-inflammatory effects of TGF-β are blunted by overexpression of SMAD7 in IBD. Mongersen is an antisense oligonucleotide developed to suppress
the expression of SMAD7 and reveal the anti-inflammatory effects of TGF-β. Indeed, a recent
phase II trial of Mongersen led to a clinical response that was sustained for over three months,
indicating enduring therapeutic effects. As further molecular insights are gained into the
pathophysiological mechanisms of IBD, next-generation therapies will be directed to
modulating the mucosal barrier, microbiota, and endoplasmic reticulum stress.10
Worldwide, atherosclerotic cardiovascular disease (ASCVD) is one of the leading causes
of death, and in the U.S. accounts for ~$ 315 billion health care expenditure each year. One key
conceptual advancement in efforts to optimally manage ASCVD was the role of atherosclerotic
plaques in the pathophysiology of ischemic vascular disease and the relationship between
circulating levels of cholesterol and plaque formation. Indeed, inhibiting plaque formation by
5

controlling serum cholesterol levels is one of the essential therapeutic strategies to prevent
ASCVD and cardiovascular mortality. In that context, the field was transformed by the
molecular discovery 40 years ago that statins could inhibit HMGCoA reductase, the rate-limiting
enzyme in the de novo synthesis of cholesterol. This was a breakthrough in the management of
hypercholesterolemia syndromes, and statins are first line therapy to reduce serum cholesterol
levels and the incidence of ASCVD and cardiovascular mortality. However, many patients
experience muscle symptoms and other adverse events that limit compliance. Further, ~70% do
not attain LDL-C treatment targets even when adherent to statin therapy. Moreover, recent
practice guidelines recommend statin therapy that expands the populations requiring adequate
control of serum cholesterol, doubling the number of patients to about 13 million, and the
associated cost of treatment. These considerations underscore the need for improved therapies
to control serum cholesterol and ASCVD. This field recently has been transformed again, and
Shantha and Robinson11 describe the 2003 discovery of PCSK-9 as a novel enzyme expressed in
liver, intestine, kidney and the nervous system. It resides in a complex with LDL receptors
enhancing endosomal and lysosomal degradation of those receptors. Gain of function
mutations of PCSK-9 reduce LDL receptors on the cell surface, resulting in familial
hypercholesterolemia associated with increased ASCVD. Conversely, patients with loss of
function mutations in PCSK-9 have elevated amounts of LDL receptors at the cell surface, with
reduced circulating levels of cholesterol and reduced risk for ASCVD. Based on these novel
mechanistic insights, monoclonal antibodies that inhibit PCSK-9 were developed as a treatment
to raise cell surface LDL receptors and lower circulating cholesterol levels and ASCVD risk.
Indeed, alirocumab and evolocumab reduce serum cholesterol in statin-naïve and statinresistant patients. Moreover, meta-analyses suggest that these agents significantly reduce
ASCVD and overall mortality, without significant treatment-related adverse events. Alirocumab
and evolocumab were approved in the summer of 2015 for patients on maximal statin therapy
with familial hypercholesterolemia or cardiovascular disease who might benefit from additional
cholesterol lowering.
6

Beyond the formation of cholesterol plaques, the other key component contributing to
the pathophysiology of ASCVD is platelet activation and the formation of thrombi which
occlude affected vessels. Molecular dissection of platelet signaling has revealed key points of
intervention to reduce platelet activation and thrombus formation. Contact with a plaque
induces receptor-mediated platelet adherence and deposition. Subsequent release of ADP and
thromboxane cause the rapid activation and local recruitment of additional platelets. In turn,
the activated platelet plasma membrane serves as a critical receptor and cofactor for initiating
coagulation with the ultimate generation of thrombin enabling formation of an insoluble, crosslinked fibrin clot. While normal hemostasis ensues when the platelet-fibrin thrombus seals
wound, thrombus formation in the context of an atherosclerotic plaque produces pathologic
vessel occlusion. First generation approaches to blocking thrombus formation leveraged the
discovery that thromboxane, a key mediator of platelet activation, was synthesized from
arachidonic acid through a cascade in which cyclooxygenase was a rate limiting enzyme. Thus,
aspirin, an irreversible inhibitor of cyclooxygenase, is one mainstay of therapy to prevent
platelet activation and clot formation. The field was propelled by the discovery of the role of
P2Y purinergic receptors in mediating ADP-dependent platelet activation, and agents that block
these receptors have transformed therapeutic paradigms that prevent thrombus formation.
However, while these paradigms provide clinically significant improvements in the antithrombotic management of patients with ASCVD, absolute reduction in thrombotic events
remains relatively low and is associated with a substantial risk of major bleeding. In their
review, Bray and Holinstat12 describe next-generation molecular insights which are providing
advanced tools to manage thrombotic disease. Thus, thrombin activation is the final key step in
the coagulation pathway and a significant regulatory step in platelet activation. Platelets
express unique G-protein coupled protease-activated receptors (PARs) which are activated
when thrombin binds to and cleaves the amino-terminus, initiating a cascade of intracellular
calcium signaling mediating platelet activation. Recognition of the importance of PARs in
platelet activation and thrombus formation was rapidly translated in a biopharmaceutical
7

program to develop orally-available receptor antagonists. In the summer of 2014, the first PAR
antagonist, vorapaxar, was approved by the FDA to prevent recurrent cardiovascular events in
patients with a history of ASCVD.
These examples underscore the evolving significance of the Bioinnovation Enterprise in
translating molecular discoveries in the laboratory into novel healthcare paradigms that
transform disease therapy and prevention in patients and populations. This significance is
further highlighted by George, Vaid and Summer13 who review the recent approval of
nintedanib and pirfenidone for the treatment of idiopathic pulmonary fibrosis. Following
decades of unfruitful exploration, these inhibitors of inflammation, fibroblast function and
collagen deposition are the first approved treatments for this devastating disease and
considered to be highly impactful.8 On the horizon, emerging platform technologies are moving
from the laboratory bench to the bedside to transform our most basic concepts of patient
management. In that context, Subbotina et al.14 review the promise of morpholino
oligonucleotides for gene editing to correct what was previously considered to be irreversible
disease-causing mutations. Further, advances in biology are complemented by innovations in
bioengineering, and Iezzi15 reviews transformative progress at the interface of brain and
machine in the form of retinal implants to restore vision. Additionally, acceleration of
translation reflecting the revolution in biology, in turn, drives the evolution of companion
structures required to maximize the impact of these transformative discoveries. Berry 16
provides a cogent review of innovations in clinical trial designs that optimizes drug efficacy with
molecular and pathophysiological disease subtype. Moreover, Fujita17 describes innovations in
regulatory sciences in Japan to overcome the unique challenges of deploying regenerative cell
therapies to patients and populations.
The Bioinnovation Enterprise is poised to transform the rapid pace of knowledge
generation in pathobiology into therapeutic innovations for global populations. The impact of
this transformation on the drug development and healthcare delivery landscapes will
undoubtedly escalate over the coming years, driven by the dual engines of exponential
8

knowledge growth and commoditized technologies with de-risking pipeline development and
de-escalating costs. One cautionary note in this otherwise optimistic paradigm is indeed the
cost of this remarkable innovation to individuals and society. For diseases involving millions of
patients and transformative therapies priced at $10,000 to $100,000 a year, the
unsustainability of the model is revealed by simple arithmetic. Biopharmaceutical executives,
investors, third party payors and governmental agencies must collaborate to define the
appropriate balance between individual patient health, society’s best interests, and a fair
return on investment that will propel the next generation solutions.
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